Wall Street loves a dominant player, and Eli Lilly (NYSE: LLY) looks unstoppable with its obesity blockbusters printing money ...

Doctors and many patients say GLP-1 drugs can help solve the growing problem of obesity. But some bristle at the thought that ...

Two new studies that have been published recently show that people who have been taking weight loss drugs may have encountered an increased risk of serious eye conditions and vision loss.

WITH the price of Mounjaro set to rise and concerns about long-term affordability and access, many may be looking to turn to alternative treatments, like Wegovy. But how do the two weight loss ...

Hims & Hers saw 73% revenue growth, driven by subscriber gains and ARPU hikes. Read here for an in-depth investment analysis ...

Madrigal Pharmaceuticals, Inc.'s Rezdiffra saw Q2 net sales soar 55% to $212.8M amid strong growth. EU approval expected by ...

Studies have linked GLP-1 medications to various eye conditions, some of which may lead to vision loss. Despite these ...

Uncover the truth about GLP-1 weight loss drugs like Ozempic and Mounjaro. Learn how they work, who benefits most, potential risks, and why experts say they can be game-changing tools for fighting ...

“From 2019 to 2024, the percentage of adult patients with a diagnosis of overweight or obesity increased 50.7 percent, and ...

A recent study aimed to assess evidence on the safety and complications of preoperative glucagon-like peptide-1 (GLP-1) ...

A 2025 survey highlights growing momentum for multi-indication drug development, with opportunities in innovative trial ...

Some women are reporting that taking GLP-1 injections, more commonly known by brand names like Ozempic and Mounjaro, has produced an unsightly and uncomfortable side effect ...